Identification of forced degradation products of lacosamide by LC-QQLIT-MS and LC-IT/TOF-MS

• Autorzy: Zhou Na , Li Tao , Ai Lianfeng , Guo Chunhai , Zhang Juan , Fu Shan , Wang Qiao

Identyfikatory

DOI

1556/1326.2018.00279

• Języki publikacji: EN

Abstrakty

EN

Lacosamide, a new type of antiepileptic drug, was subjected to forced degradation under the conditions of hydrolysis (acidic and alkaline), oxidation, dry heat, and photolysis to characterize its possible degradation products. The drug showed significant degradation under acidic, alkaline and oxidative conditions. The degradation products were separated on an Agilent Zorbax SB-C18 column with gradient elution using a mobile phase consisting of acetonitrile and ammonium acetate (0.002 mol/L) with formic acid as additive. A combination of liquid chromatography hybrid triple quadrupole-linear ion trap mass spectrometry (LC–QqLIT-MS) and liquid chromatography hybrid ion trap/time-of-flight mass spectrometry (LC-IT/TOF-MS) was used to identify degradation products. A total of 7 products including 4 novel degradation products were characterized. The mechanisms of degradation products of lacosamide were discussed. Application of the method to study degradation products of lacosamide provided fragment information, allowing further investigation of the degradation pathways and intrinsic stability of the drug.

Słowa kluczowe

EN

lacosamide; forced degradation; LC–QqLIT-MS; LC–IT/TOF-MS; characterization

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2019
• Tom: Vol. 31, no. 1
• Strony: 12--18
• Opis fizyczny: Bibliogr. 19 poz., rys., tab.

Twórcy

autor

Zhou Na

• Department of Pharmaceutical Analysis, School of Pharmacy, Hebei Medical University, Shijiazhuang, 050017, P. R. China

autor

Li Tao

• Department of Pharmaceutical Analysis, School of Pharmacy, Hebei Medical University, Shijiazhuang, 050017, P. R. China
• Department of Pharmacy, Hebei eye hospital, Xingtai, 054000, P. R. China

autor

Ai Lianfeng

• Hebei Entry-Exit Inspection and Quarantine Bureau, Shijiazhuang, 050051, P. R. China

autor

Guo Chunhai

• Hebei Entry-Exit Inspection and Quarantine Bureau, Shijiazhuang, 050051, P. R. China

autor

Zhang Juan

• Department of Pharmaceutical Analysis, School of Pharmacy, Hebei Medical University, Shijiazhuang, 050017, P. R. China

autor

Fu Shan

• Department of Pharmaceutical Analysis, School of Pharmacy, Hebei Medical University, Shijiazhuang, 050017, P. R. China

autor

Wang Qiao

• Department of Pharmaceutical Analysis, School of Pharmacy, Hebei Medical University, Shijiazhuang, 050017, P. R. China

Bibliografia

• [1] Wang, X. F. Int. J. Intern. Med. 1988, 11, 511–513.
• [2] Jin, Z. B.; Sun, W. H. Chin. J. New Drugs 2005, 5, 544–547.
• [3] Spanaki, M. V.; Barkley, G. L. Neurology: Clin. Pract. 2012, 9, 236–241.
• [4] Chung, S.; Sperling, M. R.; Biton, V., Epilepsia 2010, 1, 27.
• [5] Harris, J. A.; Murphy, J. A. Ann. Pharmacother 2009, 43, 1809–1817.
• [6] Halford, J. J.; Lapointe, M. Epilepsy Curr. 2009, 9, 1–9.
• [7] Liu, Z. Y.; Zhang, H. H.; Chen, X. H.; Zhou, X. N.; Wan, L.; Sun, Z. L. Int. J. Mass Spectrom. 2011, 303, 90–96.
• [8] Namdev, D.; Borkar, R. M.; Raju, B.; Kalariya, P. D.; Rahangdale, V. T.; Gananadhamu, S.; Srinivas, R. J. Pharm. Biomed. Anal. 2014, 88, 245–255.
• [9] Handa, T.; Singh, S.; Singh, I. P. J. Pharm. Biomed. Anal. 2014, 89, 6–17.
• [10] Rao, R. N.; Ramachandra, B.; Sravan, B.; Khalid, S. J. Pharm. Biomed. Anal. 2014, 89, 28–33.
• [11] Ramesh, T.; Rao, P. N.; Rao, R. N. J. Pharm. Biomed. Anal. 2014, 88, 609–616.
• [12] ICH, , Stability Testing of New Drug Substance and Products Q1A(R2), in: International Conference on Harmonization, IFPMA, Geneva, 2003.
• [13] Tiwari, R. N.; Bonde, C. G. J. Liq. Chromatogr. R T 2014, 37, 2046–2061.
• [14] Patel, A.; Suhagia, B. N.; Patwari, A. Int. J. Pharm. Pharm. Sci. 2013, 6, 593–599.
• [15] Ramisetti, N. R.; Kuntamukkala, R.; Lakshetti, S.; Sripadi, P. J. Pharm. Biomed. Anal. 2014, 95, 256–264.
• [16] Molleti, S.; Rao, V.; Jayaveera, K. N. Pharma. Chem. 2013, 5, 81–89.
• [17] Parmar, M. D.; Nimavat, K. S.; Vyas, K. B.; Rao, D. V. N. S.; Pande, R. Int. J. Pharm. Res. Scholars 2012, 1, 40–47.
• [18] Chakravarthy, V. K.; Sankar, D. G. Rasayan J. Chem. 2012, 5, 293–310.
• [19] Chakravarthy, V. K.; Shankar, D. G. Rasayan J. Chem. 2011, 4, 744–752.

Uwagi

PL

Opracowanie rekordu w ramach umowy 509/P-DUN/2018 ze środków MNiSW przeznaczonych na działalność upowszechniającą naukę (2019).